Lenvaitnib is available in 4 mg and 10 mg capsule dosages for oral consumption.

**Radioactive Iodine-refractory Differentiated Thyroid Cancer (DTC)**

- 24 mg orally once a day.

**Advanced Renal Cell Carcinoma (RCC)**

- First-line treatment: 20 mg orally once a day in combination with pembrolizumab for up to two years; then can be given as monotherapy.

- Previously treated disease: 18 mg orally once daily in combination with everolimus.

**Unresectable Hepatocellular Carcinoma (HCC)******

The suggested dose should be determined based on the patient's body weight:

- 12 mg orally once a day for patients' body weight greater than or equal to 60 kg.

- 8 mg orally once a day for patients weighing less than 60 kg.

**Advanced Endometrial Carcinoma**

- 20 mg orally once daily; for patients with non-microsatellite instability-high (MSI-H) or non-mismatch repair deficient (dMMR) progressive disease who are not candidates for X-ray therapy or curative surgery, use with pembrolizumab.

Dosing modifications are necessary for patients with hepatic and renal impairments. Lenvatinib is metabolized enzymatically in the liver by CYP450 isoform CYP3A and aldehyde oxidase and excreted from the body in the form of feces and urine.